Polyclonal Antibody to Aspartate Aminotransferase 2 (AST2)
| Code | Size | Price |
|---|
| PAD853Mu01-20ul | 20ul | £88.00 |
Quantity:
| PAD853Mu01-100ul | 100ul | £165.00 |
Quantity:
| PAD853Mu01-200ul | 200ul | £223.00 |
Quantity:
| PAD853Mu01-1ml | 1ml | £512.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GOT2; MitAAT; KATIV; KAT4; FABP-1; Plasma membrane-associated fatty acid-binding protein; Glutamic-Oxaloacetic Transaminase 2,Mitochondrial; Kynurenine Aminotransferase IV
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Aspartate Aminotransferase 2
Reactivity:
Hu;Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://pubmed.ncbi.nlm.nih.gov/32726686/;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Aspartate Aminotransferase 2 (AST2) | RPD853Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||